Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
Sanofi SA SAN
News
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Press Release: Availability of the Q3 2024 Aide mémoire
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also 'on notice'
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Sanofi Teams Up With RadioMedix, Orano in $352 Million Deal for Cancer Therapy — Update
Sanofi Teams Up With RadioMedix, Orano Med to Develop Rare Cancer Treatment
Sanofi's Dupixent Drug Achieves Improvement for Skin Diseases
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
United States